SAB Biotherapeutics SAB-142 Shows C-Peptide Preservation in Type 1 Diabetes Phase 1 Trial

Key Takeaways

• All 4 Type 1 diabetes patients receiving SAB-142 demonstrated C-peptide preservation, indicating maintained insulin production
• Three of four participants showed ‘super responder’ profiles with T cell exhaustion, suggesting strong immune modulation
• Patients experienced improved glycemic control, potentially reducing long-term diabetes complications

---

SAB Biotherapeutics (Nasdaq: SABS) reported promising Phase 1 clinical trial results for SAB-142, showing C-peptide preservation in all Type 1 diabetes patients treated with the experimental therapy.

The clinical-stage biopharmaceutical company presented additional data from its SAB-142 Phase 1 trial at the International Diabetes Summit (IDS) 2026, demonstrating the potential of its fully human anti-thymocyte immunoglobulin (hATG) approach for treating established autoimmune Type 1 diabetes.

Clinical Results Show Promise

In the small cohort of adult patients with established Type 1 diabetes, SAB-142 demonstrated consistent efficacy across key measures. All four participants maintained C-peptide levels, a critical biomarker indicating the pancreas continues producing insulin. C-peptide preservation is particularly significant in Type 1 diabetes, where autoimmune destruction typically eliminates insulin-producing beta cells.

Three participants exhibited what researchers termed a “super responder profile,” characterized by T cell exhaustion - a mechanism that may help control the autoimmune attack on pancreatic beta cells. This immune modulation represents a potential breakthrough in treating the underlying cause of Type 1 diabetes rather than just managing symptoms.

Improved Metabolic Control

Beyond biomarker improvements, patients receiving SAB-142 showed enhanced glycemic control, suggesting real-world benefits for diabetes management. Better glucose control typically translates to reduced risk of long-term complications including cardiovascular disease, kidney damage, and neuropathy.

Market and Clinical Implications

The results position SAB-142 as a potential disease-modifying therapy for Type 1 diabetes, a market currently dominated by insulin replacement therapies. While the Phase 1 trial involved only four patients, the consistent positive responses across all participants provide encouraging signals for larger clinical studies.

SAB Biotherapeutics’ hATG approach represents a novel strategy in autoimmune disease treatment, potentially offering advantages over existing immunosuppressive therapies through more targeted immune modulation.

The company has not yet announced timeline details for Phase 2 trials, but these preliminary results may accelerate development discussions with regulatory authorities.

---

Frequently Asked Questions

What does C-peptide preservation mean for Type 1 diabetes patients?

C-peptide preservation indicates that insulin-producing beta cells in the pancreas remain functional, potentially reducing insulin dependency and improving long-term diabetes management compared to complete beta cell loss.

When will SAB-142 be available for Type 1 diabetes treatment?

SAB-142 is currently in Phase 1 trials. The drug would need to complete Phase 2 and Phase 3 trials and receive FDA approval, which typically takes several years from current stage.

How does SAB-142 differ from current Type 1 diabetes treatments?

Unlike insulin therapy which replaces missing hormone, SAB-142 aims to modify the autoimmune disease process itself, potentially preserving natural insulin production and addressing the root cause of Type 1 diabetes.